Scancell lauds another six months of progress The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic". [View article] Thursday 31 January 2019 13:41 Categories: Immunobody Media Coverage Modi-1 Modi-2 Moditope SCIB1 Year - 2019 Previous Post << >> Next Post